To print: Select File and then Print from your browser's menu

Title: ERRATUM: Gefitinib (Iressa) Active Against Advanced Colorectal Cancer: Presented at CFS

"ERRATUM: Gefitinib (Iressa) Active Against Advanced Colorectal Cancer: Presented at CFS"

There was an error in our DG Dispatch (Nov. 12, 2004) based on a presentation at the Chemotherapy Foundation Symposium. We erroneously reported on the study regimen. Treatment was as follows: Subjects underwent 14-day treatment cycles. In the first cycle, they received oxaliplatin 85 mg/m[² in a 2-hour intravenous installation on the first day. On the first and second days, they also received leucovorin 200 mg/m² intravenously, as well as 5-FU 400 mg/m² in an intravenous push. On those days, patients also received 5-FU 600 mg/m² for hours 2 to 24. In the second and subsequent cycles, patients received 500 mg of gefitinib orally once daily, along with the combination chemotherapy regimen.

We apologise to the manufacturer for having published inaccurate information on their product.

We are committed to providing the most accurate, relevant and balanced information for physicians worldwide and have devoted considerable resources to ensuring this. We deeply regret this error.

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.